http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2441906-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_979e3be24194f43ec0335bf012d62faf |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-00 |
| filingDate | 2009-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3b9877c36dc4a8e5da6d522b0284f05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f1e34d16e68e0b34ea01444c8506652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a27acd549b946d4a76e81471a59a90c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_971a5cd192ff1479d704d3fcab7a733c |
| publicationDate | 2012-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2441906-C2 |
| titleOfInvention | Composition comprising low-molecular fragments of peptidoglicane of gram-negative bacteria for preventing or treating of human diseases |
| abstract | FIELD: pharmacology. n SUBSTANCE: invention relates to the area of biotechnology. The pharmaceutical composition comprising three components of bacterial nature are described: (1) beta-N-acetyl-D-glucosaminyl-(1-4)-N-acetyl-D-muramoyl-L-alanine-D-isoglutaminyl-meso-diaminopimyelinic acid (GMtri), (2) beta-N-acetyl-D-glucosaminyl-(1-4)-N-acetyl-D-muramoyl-L-alanine-D-isoglutaminyl-meso-diaminopimyeloid-D-alanine (GMtetra), (3) GMtetra dimer (di-GMtetra) in which tetrameric residues of GMtetra are held together by an amide bond between carboxyl group of terminal D-alanine of one residue and w-amino group of meso-diaminopimyelinic acid of the other. The composition is proposed for obtaining a medicinal product for preventing or treating of diseases and conditions caused by bacteria that require enhancing nonspecific resistance of the organism to bacteria, diseases caused by Human Immuno-deficiency Virus (HIV) and herpes simplex virus, or diseases and conditions that require the organism's properties of malignant tumor rejection or myelopoiesis stimulation. A set for preventing or treating of diseases and conditions that comprses the above composition in a dosage form is disclosed, too. n EFFECT: increased effectiveness of certain medicines. n 16 cl, 8 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2699040-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2563354-C2 |
| priorityDate | 2009-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 276.